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Abstract 
Background: The steadily growing world population and our ever luxurious life style, along with the simultaneously 
decreasing fossil resources has confronted modern society with the issue and need of finding renewable routes to 
accommodate for our demands. Shifting the production pipeline from raw oil to biomass requires efficient processes 
for numerous platform chemicals being produced with high yield, high titer and high productivity.
Results: In the present work, we established a de novo bio-based production process for the two carbon-5 platform 
chemicals 5-aminovalerate and glutarate on basis of the lysine-hyperproducing strain Corynebacterium glutamicum 
LYS-12. Upon heterologous implementation of the Pseudomonas putida genes davA, encoding 5-aminovaleramidase 
and davB, encoding lysine monooxygenase, 5-aminovalerate production was established. Related to the presence 
of endogenous genes coding for 5-aminovalerate transaminase (gabT) and glutarate semialdehyde dehydrogenase, 
5-aminovalerate was partially converted to glutarate. Moreover, residual l-lysine was secreted as by-product. The issue 
of by-product formation was then addressed by deletion of the lysE gene, encoding the l-lysine exporter. Additionally, 
a putative gabT gene was deleted to enhance 5-aminovalerate production. To fully exploit the performance of the 
optimized strain, fed-batch fermentation was carried out producing 28 g L−1 5-aminovalerate with a maximal space–
time yield of 0.9 g L−1 h−1.
Conclusions: The present study describes the construction of a recombinant microbial cell factory for the produc-
tion of carbon-5 platform chemicals. Beyond a basic proof-of-concept, we were able to specifically increase the 
production flux of 5-aminovalerate thereby generating a strain with excellent production performance. Additional 
improvement can be expected by removal of remaining by-product formation and bottlenecks, associated to the 
terminal pathway, to generate a strain being applicable as centerpiece for a bio-based production of 5-aminovalerate.
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Background
Today’s petrochemical industry is challenged by the ever-
increasing demand for commodity chemicals, polymer 
materials and related compounds, which is additionally 
aggravated by the ever-decreasing accessibility of fossil 
resources as base material [1]. Hence, substantial effort 
has been made for providing alternative “green” routes 
to produce platform chemicals through microbial fer-
mentation processes. Compounds of interest comprise 
organic acids [2] such as succinate [3–5], lactate [6], and 
itaconic acid [7], diamines including putrescine [8, 9] and 
cadaverine [10–14] and diols [15–18], all being appli-
cable as building blocks for bio-based plastics. In this 
regards, also 5-aminovalerate and glutarate are attractive 
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carbon-5 building blocks for the production of nylon 
from renewable feedstocks [19, 20]. By now, Escheri-
chia coli has been in the focus of interest as platform for 
either de novo biosynthesis [19] of 5-aminovalerate and 
glutarate or for biotransformation [20–22] thereof from 
l-lysine. As 5-aminovalerate and glutarate are degrada-
tion products of the proteinogenic amino acid l-lysine, 
we choose the non-pathogenic Gram-positive soil bac-
terium Corynebacterium glutamicum, a well-established 
industrial l-lysine producer [1], as metabolic chassis for 
the production of these carbon-5 platform chemicals. 
Beyond the excellent availability of genetic tools [23], and 
knowledge of its physiology and large-scale fermenta-
tion [24, 25], engineered C. glutamicum has only recently 
been established as centerpiece for the production of 
l-lysine-derived cadaverine within a pipeline towards the 
manufacturing of the fully bio-based polyamide PA5.10 
[13]. In this work, the metabolic pathway from l-lysine 
towards 5-aminovalerate was reconstituted by stable 
genome-based implementation of the Pseudomonas 
putida KT2440 genes davB, encoding lysine monooxy-
genase, and davA, encoding 5-aminovaleramide amidase 
(Fig. 1)—a strategy previously established for E. coli [19, 
21]. Glutarate production relied on an endogenous path-
way (Fig. 1). Though experimentally shown [26], full and 
unambiguous annotation of the genes coding for the 
required enzymes 5-aminovalerate transaminase (GabT) 
and glutarate semialdehyde dehydrogenase (GabD) is 
missing so far (Fig.  1). We further engineered the basic 
producer by elimination of by-product formation and 
focusing the production flux towards 5-aminovalerate. 
Production was subsequently benchmarked in fed-batch 
fermentation.
Results
Recombinant expression of the davBA genes establishes 
5‑aminovalerate and glutarate production in C. 
glutamicum
Upon implementation of the P. putida genes davBA in 
the genome of C. glutamicum LYS-12, this l-lysine-hyper 
Fig. 1 Metabolic pathway design for the production of 5-aminovalerate and glutarate in Corynebacterium glutamicum starting from the pathway 
precursor l-lysine. Heterologous genes (davBA) from Pseudomonas putida KT2440 were used to reconstruct the 5-aminovalerate pathway compris-
ing lysine monooxygenase (DavB) and 5-aminovaleramidase (DavA). Genes under control of the constitutive tuf-promotor were integrated in the 
bioD locus of the genome of C. glutamicum LYS-12. Glutarate production from 5-aminovalerate via the activity of 5-aminovalerate transaminase 
(GabT) and glutarate semialdehyde dehydrogenase (GabD) relied on endogenous reaction with no or promiscuous gene annotation. Potential 
candidates were identified by BLASTX search using sequence information of the P. putida genes gabT (davT, PP_0213)a and gabD (davD, PP_0214)b
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producing strain was re-programmed for 5-aminovaler-
ate and glutarate production. Genome-based integra-
tion of the construct (Fig.  1) was first verified by PCR 
analysis. Cloning-associated mutations were subse-
quently excluded by sequencing. Functional expression 
of lysine monooxygenase (DavB) and 5-aminovalerami-
dase (DavA) was validated by in  vitro activity measure-
ment. The underlying assay allowed parallel investigation 
of l-lysine consumption, related to DavB activity, and 
5-aminovalerate production, related to DavA activity. 
In crude cell extracts of the recombinant AVA-1 strain 
both lysine consumption (4.1 ±  0.4  mmol  L−1  h−1) and 
5-aminovalerate production (1.8  ±  0.6  mmol  L−1  h−1) 
was observed. As no conversion took place in the par-
ent strain C. glutamicum LYS-12, this could be specifi-
cally attributed to the heterologous davBA expression. 
Additional proof for the functional operation of the path-
way came from cultivation experiments. During growth 
of C. glutamicum AVA-1 in glucose minimal medium, 
both 5-aminovalerate and glutarate were produced and 
secreted into the medium (Fig. 2a). The production was 
growth-associated. After depletion of glucose, 5-amino-
valerate and glutarate accumulation stopped at a titer of 
5.4 and 6.5  mM, identifying glutarate as major product 
in the AVA-1 strain. The pathway precursor l-lysine was 
also found in the culture supernatant, though it was only 
secreted to a lower extent of 2.9 mM (Fig. 2a). All prod-
ucts were produced constantly and we could not observe 
any production shift throughout the cultivation (Fig. 2b), 
which allowed precise and representative determina-
tion of the yields (Table 1). Glutarate was produced most 
efficiently (123 mmol mol−1). In comparison, the 5-ami-
novalerate yield was 24  % lower and l-lysine secretion 
only contributed to about 19 % of the total product for-
mation. The observed production pattern indicated that 
the l-lysine exporter protein LysE obviously competed 
with the activity of lysine monooxygenase, catalyzing 
the initial step of the 5-aminovalerate/glutarate pathway. 
Similarly, 5-aminovalerate export competed with the 
endogenous transamination reaction (Fig.  1). The pref-
erence of the cell to rather form glutarate than 5-amino-
valerate indicated that transamination was more efficient 
than export. However, once secreted, 5-aminovaler-
ate was not channeled back into the glutarate pathway. 
Indeed, when C. glutamicum LYS-12 was grown in the 
presence of 5-aminovalerate, the concentration of 5-ami-
novalerate did not decrease over the cultivation time and 
no glutarate formation was observed. 
Secretion of the by‑production l‑lysine is eliminated by the 
deletion of lysE
To account for the undesired secretion of l-lysine in the 
basic strain AVA-1, the lysE gene, encoding for the lysine 
exporter, was deleted from the genome. For this purpose, 
a shortened DNA fragment, lacking 575  bp of the cod-
ing region of lysE, was used to replace the native gene. 
Correct modification was identified by PCR analysis. 
Deletion of lysE positively affected the production of the 
desired C5-compounds in the second-generation strain 
C. glutamicum AVA-2. Titer (Fig. 2c) and yield (Table 1) 
were increased for both glutarate and 5-aminovaler-
ate. l-Lysine excretion was fully eliminated. The excess 
carbon gained from exporter deletion was mostly used 
in favor of glutarate production. We also observed an 
increase in the biomass yield, as compared to the parent 
C. glutamicum AVA-1 strain (Table  1). Obviously, bio-
mass formation appeared as newly arising competitor for 
the additionally available carbon. The specific growth rate 
was hardly affected by lysE deletion, whereas the specific 
glucose uptake rate was 30  % lower (Table  1). Overall, 
this resulted in a decreased specific production rate for 
both glutarate and 5-aminovalerate, despite the increased 
yield (Table 1).
Identification and elimination of 5‑aminovalerate 
transaminase selectively increases the 5‑aminovalerate 
production flux
When aiming at the production of 5-aminovalerate, with-
drawal of the product via the glutarate pathway has to 
be circumvented. The underlying biochemical reactions 
were, however not fully identified in C. glutamicum so 
far. For P. putida it is known, that two enzymes namely 
5-aminovalerate transaminase, encoded by gabT (davT), 
and glutarate semialdehyde dehydrogenase, encoded by 
gabD (davD) are responsible for glutarate formation from 
5-aminovalerate [27]. For the glutarate semialdehyde 
dehydrogenase encoding gene, two potential candidates 
are annotated in the genome of C. glutamicum (Fig. 1). A 
gene annotation for the 5-aminovalerate transaminase is, 
however completely missing. To identify potential genes 
in the genome of C. glutamicum, a nucleotide BLASTX 
search was carried out using the gabD and gabT sequence 
of P. putida as input. From the obtained set of candidates, 
hits with best E-value were evaluated in more detail, con-
sidering existing annotation and genomic localization 
(Fig.  1). The most promising candidates were the genes 
NCgl0462 (gabT) and NCgl0463 (gabD) as they show high 
similarity scores to the P. putida sequence and exhibit the 
same genomic organization as the P. putida genes as two 
adjacent open reading frames. For improving 5-amino-
valerate production, we selected the gabT gene, anno-
tated as 4-aminobutyrate aminotransferase (Fig.  1), as 
deletion target to immediately cut the glutarate pathway 
at the level of 5-aminovalerate and to avoid accumulation 
of the pathway intermediate glutarate semialdehyde. The 
coding sequence of the gene was fully deleted as validated 
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Fig. 2 Growth and production characteristics of 5-aminovalerate and glutarate producing C. glutamicum. The C. glutamicum strains AVA-1 (a, b), 
AVA-2 (c, d) and AVA-3 (e, f) were cultivated in shake flasks at 30 °C in a chemically defined medium. The cultivation profiles show growth, product 
formation and glucose consumption over time and represent mean values and corresponding standard deviations from three biological replicates 
(a, c, e). Yields were determined as slope from the linear correlation of glucose consumption and production formation from three biological repli-
cates (b, d, f)
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by PCR analysis, which revealed a 1347  bp-shortened 
DNA fragment in C. glutamicum AVA-3 as compared to 
the parent strain. The strategy for generating the third-
generation strain C. glutamicum AVA-3 proved highly 
beneficial. The product 5-aminovalerate accumulated up 
to 14 mM (Fig. 2e), which was more than twice as high 
as compared to the ancestor strains. The mutant exhib-
ited highest yield (275  mmol  mol−1) and, in particular, 
highest specific production rate, despite impaired growth 
and glucose uptake (Table 1). The latter might partly be 
related to intracellular accumulation of l-lysine, 5-ami-
novaleramid and 5-aminovalerate as response to the net-
work perturbation at the level of LysE and GabT. Though 
small, a secretion flux for glutarate remained indicating 
residual in  vivo transamination of 5-aminovalerate. The 
strong decrease in the glutarate yield (Table 1), however, 
clearly showed that the major contributing enzyme had 
been eliminated by NCgl0462 deletion.
Excellent performance of the 5‑aminovalerate‑producing 
C. glutamicum strain AVA‑3 under fed‑batch conditions
To assess the performance of the designed production 
strain under conditions more relevant for an industrial 
process, we benchmarked 5-aminovalerate production by 
this strain in a fed-batch process on a glucose-molasses 
medium. In the initial batch phase of the fermentation, 
we observed exponential growth along with 5-amino-
valerate production (Fig. 4a). After a process time of 15 h, 
the initially supplied sugar (120 g L−1) was depleted and 
the feed phase was started. Feeding pulses were applied 
to maintain sugar concentration above 20 g L−1. The level 
of 5-aminovalerate continuously increased from 12 g L−1 
at the end of the batch phase to a final titer of 28 g L−1 
after 50  h. Glutarate was concomitantly secreted and 
accumulated up to 7  g  L−1 (Fig.  3a). Proper determina-
tion of the optical density as indicator for biomass con-
centration was hampered in the feed phase due to cell 
agglomeration and wall-associated growth. The final 
biomass concentration of 70  g  L−1 was hence deter-
mined gravimetrically as cell dry mass from the total 
reactor content at the end of the process. Trehalose was 
the only other by-product that accumulated in notewor-
thy amounts (7  g  L−1). When evaluating the efficiency 
for 5-aminovalerate production throughout the process 
phases (Fig. 3b), slightly different yields were obtained for 
the batch (0.11 g g−1) and the feed phase (0.13 g g−1). The 
glutarate yield increased by threefold in the feed phase. 
The space–time yield for 5-aminovalerate was maximal 
in the batch phase with a rate up to 0.9 g L−1 h−1. Over 
the full process time, production occurred at more than 
half-maximum rate (0.5 g L−1 h−1).
Discussion
In recent years, l-lysine-derived compounds, e.g. cadav-
erine [13, 28, 29], glutarate [19, 22, 26], 5-aminovalerate 
[20, 21] and pipecolic acid [30] have emerged as attrac-
tive platform building blocks, to establish bio-based 
production routes for chemicals and materials [31, 32]. 
This depicts an excellent possibility to employ existing 
l-lysine overproducers as starting point for re-engineer-
ing. Corynebacterium glutamicum is the major industrial 
workhorse for the production of l-lysine [1, 33] and—
unlike P. putida [27] and E. coli [19]—it naturally misses 
catabolic reactions for degradation of l-lysine. l-lysine 
overproducing C. glutamicum strains are hence ideal 
metabolic chassis for establishing bio-based fermentation 
Table 1 Growth and production performance of the C. glutamicum strains AVA-1, AVA-2 and AVA-3 during batch cultiva-
tion in shake flasks using a mineral salt medium with glucose as sole carbon source
The data represent mean values and standard deviations from three biological replicates and denote the specific rates for growth (µ), substrate uptake (qS), and 








 µ [h−1] 0.22 ± 0.04 0.20 ± 0.00 0.11 ± 0.00
 qs [mmol g
−1 h−1] 4.59 ± 0.70 3.67 ± 0.27 2.16 ± 0.07
 qAva [mmol g
−1 h−1] 0.43 ± 0.06 0.38 ± 0.01 0.59 ± 0.02
 qGlt [mmol g
−1 h−1] 0.57 ± 0.07 0.50 ± 0.00 0.05 ± 0.00
 qLys [mmol g
−1 h−1] 0.24 ± 0.04 0.00 ± 0.00 0.00 ± 0.00
Yields
 YX/S [g mol
−1] 47.6 ± 3.6 53.9 ± 1.0 51.8 ± 0.5
 YAva/S [mmol mol
−1] 97.6 ± 2.0 104.9 ± 1.8 274.9 ± 2.9
 YGlt/S [mmol mol
−1] 123.4 ± 2.4 140.7 ± 5.6 21.8 ± 1.4
 YLys/S [mmol mol
−1] 52.6 ± 0.9 0.0 ± 0.0 0.0 ± 0.0
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processes for these interesting compounds, as there are 
no side-reactions competing with the target product 
formation. In this work, we established a de novo pro-
duction process for the carbon-5 platform chemicals 
5-aminovalerate and glutarate on basis of C. glutamicum 
LYS-12 [34]. These are promising building blocks for bio-
based polyamides and polyesters [19], when polymerized 
with appropriate counterparts such as caprolactame [20] 
and diamines [13], and beyond serve as platform chemi-
cals [22].
Expression of davBA fills the gap for de novo production 
of 5‑aminovalerate and glutarate in C. glutamicum
The strategy of using heterologous expression of the P. 
putida genes davBA for re-programming of C. glutami-
cum LYS-12 for 5-aminovalerate and glutarate produc-
tion proved highly valuable as more than 80 % of the total 
production flux was drained towards the newly imple-
mented pathway (Fig. 4). Due to the lack of l-lysine cata-
bolic reactions, additional strain modifications, required 
for E. coli-based processes [19, 22], were obsolete. About 
one-third of the rechanneled carbon was secreted as 
5-aminovalerate, whereas the major fraction was fur-
ther metabolized to glutarate via endogenous reactions 
(Fig.  4). In E. coli, production of 5-aminovalerate and 
glutarate specifically relied on heterologous expression 
of the davAB cluster (5-aminovalerate) or a combined 
expression of the davBA-davDT (gabDT) clusters (glutar-
ate) as, in contrast to C. glutamicum, endogenous genes 
for davDT are obviously missing [19, 20, 22]. Despite 
pure production of either of these compounds, E. coli 
reached maximal yields of 71 mmol mol−1 for 5-amino-
valerate and 68  mmol  mol−1 for glutarate in a de novo 
process [19], which is even far below the performance of 
the basic AVA-1 strain (Table  1). The different produc-
tion pattern for both species might be related to differ-
ences concerning re-uptake of 5-aminovalerate. E. coli 
efficiently converts externally added 5-aminovalerate 
into glutarate, when the davBA and davDT (gabDT) gene 
clusters from P. putida are concomitantly expressed [19]. 
The obviously active import system for 5-aminovalerate 
in E. coli can thus explain that there is no mixed pro-
duction of 5-aminovalerate and glutarate [19, 22]. The 
constant production characteristics of our novel strains 
(Fig.  2), however, show that once 5-aminovalerate is 
secreted, there is no re-import and further conversion to 
glutarate. In addition, we could not observe any glutar-
ate formation in C. glutamicum LYS-12 when 5-amino-
valerate was supplied to the medium. This is attributed 
to the lack of an active 5-aminovalerate uptake system 
under the tested conditions. Efficient product secretion 
without re-uptake—as found in this study for C. glutami-
cum—is highly desirable and might even become crucial 
to establish commercially feasible processes [35–37]. The 
genome-based engineering approach ensured strain sta-
bility as previously proven for manifold genetic manipu-
lations of C. glutamicum [38–42]. Overall, production of 
the target metabolites and the remaining l-lysine pro-
duction in the AVA-1 strain nicely summed up to the 
l-lysine production of the parent strain [34]. We took 
this finding as good indicator that no other by-products 
arose in noteworthy amounts, as previously shown for 
cadaverine-producing C. glutamicum [10, 11].
5‑aminovalerate production is limited by the in vivo 
activity of the heterologous pathway
The secretion of l-lysine in the AVA-1 strain revealed 
limitations in the in  vivo activity of the downstream 
Fig. 3 Production performance of the advanced 5-aminovalerate producing strain C. glutamicum AVA-3 during fed-batch fermentation. Cultivation 
profile of strain AVA-3 (a), and yields for 5-aminovalerate and glutarate achieved in the different cultivation phases (b) are shown. The data represent 
mean values from two independent fermentation experiments
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5-aminovalerate pathway. The newly implemented path-
way operated less efficiently than the cadaverine path-
way, previously established in C. glutamicum, which fully 
converted l-lysine into cadaverine by the heterologously 
implemented lysine decarboxylase [10]. Intracellular 
l-lysine accumulation in the AVA-1 strain was, however, 
sufficient to induce expression of the l-lysine exporter 
[43, 44]. Consequently, the exporter LysE competed 
with lysine monooxygenase for intracellular l-lysine 
as substrate, a phenomenon similarly found previously 
for l-lysine-derived cadaverine production, whereby 
the cadaverine export protein competed with cytosolic 
acetyl-transferase reaction that formed N-acetyl-cadav-
erine [10, 11]. We hence had a closer look at the enzyme 
activity of lysine monooxygenase and 5-aminovaler-
amidase. In vitro assays with crude cell extract revealed 
that the lysine consumption rate, reflecting lysine 
monooxygenase activity, was two times higher than the 
production rate of 5-aminovalerate, reflecting 5-amino-
valeramidase activity. Expression of both enzymes from 
the designed operon was obviously not perfectly bal-
anced. For enzymatic production of 5-aminovalerate, 
however, it was recently shown, that a 1:1 ratio of both 
enzymes is required for optimal production [21]. On 
basis of the in vitro activity, the bottleneck of the 5-ami-
novalerate pathway could on a first glance be assigned to 
5-aminovaleramidase. The initial step catalyzed by lysine 
monooxygenase is, however, massively feedback inhibited 
by 5-aminovaleramide, 5-aminovalerate, and glutarate 
at levels of 5 mM [27], likely resulting in a substantially 
reduced in  vivo activity. Moreover, from enzyme activ-
ity measurements, carried out in closed tubes, we have 
additional indication that lysine monooxygenase can 
become limiting, when oxygen supply is insufficient. In 
in vitro studies with limited oxygen supply, identical rates 
for lysine consumption and 5-aminovalerate production 
were determined (0.56 ± 0.01 mmol L−1 h−1). We hence 
cannot clearly attribute the bottleneck specifically to one 
of the enzymes and/or an imbalanced expression thereof. 
Elimination of LysE activity was therefore most straight-
forward to avoid loss of the pathway precursor l-lysine. 
Lacking any secretion system for l-lysine, the addition-
ally available carbon in the AVA-2 strain was partly used 
in favor of 5-aminovalerate and glutarate formation, and 
partly supports biomass production, as similarly found 
recently for ectoine producing C. glutamicum [45]. 
Despite the higher yields, the specific production rates 
were not increased as the in vivo activity of the heterolo-
gous pathway remained a limiting factor. The rates were 
actually lower than in the parent strain (Table 1), as the 
overall fitness (µ, qS) of the AVA-2 strain was slightly 
impaired. Further improvement of the strain perfor-
mance can thus be expected from higher davBA gene 
expression. Moreover, removal of feedback inhibition of 
lysine monooxygenase is a highly desirable, though chal-
lenging task for future strain optimization.
Fig. 4 Relative contribution of l-lysine, 5-aminovalerate and glutarate 
secretion to the overall production flux. The production of l-lysine, 
5-aminovalerate and glutarate in C. glutamicum LYS-12, AVA-1, AVA-2 
and AVA-3 is given as relative flux related the to the overall l-lysine-
based production flux, which was set to 100 %
Page 8 of 13Rohles et al. Microb Cell Fact  (2016) 15:154 
The glutarate pathway is the major competitor 
for 5‑aminovalerate production
The obtained production pattern clearly indicated 
that the endogenous transaminase reaction of the glu-
tarate pathway is dominating over the 5-aminovalerate 
export. Deletion of the putative transaminase GabT in 
the AVA-3 strain successfully redirected the production 
flux to 5-aminovalerate, though glutarate production 
was not fully eliminated. Obviously, C. glutamicum pos-
sesses more than one gene and enzyme, responsible for 
5-aminovalerate transamination. It is interesting to note 
that P. putida, which can naturally degrade l-lysine via 
the 5-aminovalerate/glutarate pathway, only possesses 
a single gabT gene variant, the lack of which prevents 
growth on l-lysine as sole carbon source [46]. Additional 
deletion of further gene candidates for gabT and gabD 
(Fig. 1) appears most straightforward to further diminish 
glutarate formation in the C. glutamicum AVA-3 strain. 
However, only few is known about their actual func-
tion, leaving a certain risk of undesired side effects upon 
deletion. As alternative strategy, the enhancement of the 
5-aminovalerate export could drive a more efficient prod-
uct secretion. Indeed, transport processes are a major 
issue of industrial processes and thus often addressed 
in the production hosts for improving production of e.g. 
cadaverine [12, 47], amorphadiene [48], l-lysine [49] and 
l-arginine [50]. In light of the strong feedback inhibition 
of lysine monooxygenase, the secretion efficiency appears 
even more relevant. Similar to E. coli [19], the transport 
mechanisms for 5-aminovalerate and associated pro-
teins are not yet known for C. glutamicum. The secretory 
capacity of C. glutamicum for non-natural compounds is, 
however, admirable as demonstrated in recent years for 
the production of ectoine [45], cadaverine [12], putres-
cine [8], and γ-amino butyric acid [51]. As shown for 
cadaverine [12], export is thereby not necessarily linked 
to a unique and specific transporter. There are likely 
transporter families with promiscuous secretory activity 
for structurally related metabolites, which might be of 
help for identification.
High‑cell density fermentation reveals excellent 
production performance
To take benefit from high cell density and the gener-
ally improved production performance [34, 45], the 
best 5-aminovalerate producer was investigated during 
fed-batch operation. C. glutamicum AVA-3 produced 
28  g  L−1 of 5-aminovalerate within only 50  h, which is 
the highest titer and productivity described so far for de 
novo production of this compound [19, 22, 26]. The max-
imal space–time yield of about 0.9  g  L−1  h−1 was even 
within the range of bio-conversion processes directly 
producing 5-aminovalerate from l-lysine [19–22]. De 
novo production as described here obviously benefits 
over such bio-transformation process, as production can 
be conducted as one-step process directly from cheap 
raw material, regularly applied for industrial fermenta-
tion [24, 25, 52]. In contrast, biotransformation requires 
successive production steps for the supply of the biocat-
alyst, e.g. whole cells or purified enzymes, and a subse-
quent conversion step for product formation. Moreover, 
it strictly relies on the pathway precursor l-lysine, addi-
tionally being produced by fermentation, requiring sub-
sequent purification. In this regard, de novo production 
is clearly more flexible, related to the broad natural sub-
strate spectrum of C. glutamicum and additional engi-
neering of assimilation routes for non-natural carbon 
sources [53, 54]. Depending on price and availability, 
alternative renewable feedstocks [29, 40, 55] or carbon-
containing waste streams from industry [54, 56] might 
become more attractive, and could hence be used for 
production.
Conclusion
In this work, we established C. glutamicum as produc-
tion platform for the polyamide building blocks 5-amino-
valerate and glutarate through genetically stable genome 
manipulation. Following the strategy of heterologous 
engineering of the 5-aminovalerate pathway from P. 
putida [19, 22, 26], combined with additional modifica-
tions that targeted by-product formation, we generated 
a strain with the highest de novo production perfor-
mance concerning titer, yield and productivity. With the 
remaining issues on the in  vivo activity of the davBA 
pathway, 5-aminovalerate export and glutarate produc-
tion, we can immediately identify future engineering tar-
gets towards strain improvement. Further optimization 
can be expected applying systems metabolic engineering 
to unravel and circumvent additional and less obvious 
bottlenecks through iterative rounds of strain analysis, 
design and genetic engineering. Similar titer, yield and 
productivity as already achieved for l-lysine [34] and 
cadaverine [13, 57] production thus appear feasible to 
leverage performance of 5-aminovalerate to industrial 
efficiency. Moreover, the AVA-2 strain already builds an 




In the present work, the ATCC 13032-derived l-lysine-
overproducing C. glutamicum strain LYS-12 [34] was 
used as host to establish 5-aminovalerate and glutar-
ate production. Reconstruction of the 5-aminovalerate 
pathway relied on the davBA genes, encoding lysine 
monooxygenase and 5-aminovaleramidase from P. 
Page 9 of 13Rohles et al. Microb Cell Fact  (2016) 15:154 
putida KT2440. Amplification of transformation vectors 
on basis of the integrative plasmid pClik int sacB [10, 58] 
was carried out in E. coli strains DH5α and NM522 (Inv-
itrogen, Carlsbad, CA, USA) [34]. All strains and plas-
mids employed in this study are listed in Table 2.
Molecular design and genetic engineering
For molecular strain, plasmid and primer design, the 
Clone Manager Professional 9 (Sci-Ed Software, Denver, 
USA) was used. For sequence similarity search towards 
identification of gabT and gabD candidates in the genome 
of C. glutamicum, the corresponding gene sequences 
from P. putida (PP_0214, gabT, davT and PP_0213, gabD, 
davD) were BLASTed (BLASTX, http://www.genome.
jp/tools/blast/) against the C. glutamicum genome, 
deposited at KEGG (http://www.genome.jp/kegg/). The 
genetic construct for genome-based integration of the 
davBA gene cluster from P. putida KT2440 comprised (i) 
500  bp-sized flanking regions as homologous recombi-
nation sites for the bioD locus (NCgl2516), (ii) a 200 bp-
sized DNA fragment of the promotor of the structural 
tuf gene (NCgl0480), and (iii) the biosynthetic genes 
davB (PP_0383) and davA (PP_0382), which were sepa-
rated by a 20-bp sized ribosomal binding site as inter-
genic region (Fig. 1). The putative gabT gene (NCgl0462) 
was fully deleted from the genome. All DNA fragments 
were amplified by PCR (2×  Phusion Flash PCR Master 
Mix, Thermo Scientific, Waltham, MA, USA; peQSTAR, 
PEQLAB Biotechnology GmbH, Erlangen, Germany) 
from genomic DNA of C. glutamicum ATCC13032 and 
P. putida KT2440, respectively, with sequence specific 
primers (Table  3). DNA fragment and vector assembly 
was carried out by the method of Gibson [59]. The reac-
tion mixture contained 157.5  mM Tris–HCl (pH 7.5), 
15.75 mM MgCl2, 15.75 mM DTT, 42 mg µL−1 PEG-800, 
0.6 mg µL−1 NAD, 25 mU µL−1 Phusion™ High-Fidelity 
DNA Polymerase (Thermo Fisher Scientific, Rochester, 
New York, USA), 7.5 mU µL−1 T5 exonuclease (Epicen-
tre, Madison, USA), 4 U µL−1 Taq Ligase (Thermo Fisher 
Scientific, Rochester, New York, USA), each 0.3  mM 
dNTPs. Prior to this, the vector was linearized via restric-
tion with BamHI (FastDigest®, Thermo Fisher Scientific, 
St. Leon-Roth, Germany). Vector amplification in the E. 
coli strains DH5α and NM522, purification of plasmid 
DNA, and its transformation into E. coli and C. glutami-
cum strains were performed as described previously [39]. 
PCR and sequence analysis (GATC Biotech AG, Kon-
stanz, Germany) were used for plasmid and strain vali-
dation. Deletion of the lysE-gene encoding the l-lysine 
exporter of C. glutamicum was conducted as described 
previously [12].
Batch cultivation in shake flasks
Corynebacterium glutamicum was grown in baffled shake 
flasks with 10  % filling volume at 30  °C and 230  rpm 
on an orbital shaker (Multitron, Infors AG, Bottmin-
gen, Switzerland; 5  cm diameter). The cultivation pro-
cedure involved one pre-culture in complex medium 
(37  g  L−1  BHI) followed by another pre-cultivation in 
minimal medium to adapt cells to the medium conditions 
of the main cultivation [60]. The main cultivation was 
carried out as triplicate in a chemically defined mineral 




 C. glutamicum LYS-12 Lysine-hyperproducing strain with 12 genome-based modifications [34]
 C. glutamicum AVA-1 LYS-12 + genome-based integration of the P. putida genes davB (PP_0383) and davA (PP_0382) encoding lysine 
monooxygenase and aminovaleramide amidase, into the bioD gene locus (NCgl2516), encoding dithiobiotin 
synthetase
This work
 C. glutamicum AVA-2 AVA-1 + deletion of lysE gene (NCgl1214), encoding the lysine exporter This work
 C. glutamicum AVA-3 AVA-2 + deletion of putative gabT gene (NCgl0462), encoding 5-aminovalerate transaminase This work
Plasmids
 pTC Expression vector for DNA-methyltransferase of C. glutamicum, ORI for E. coli and tetracycline resistance as 
selection marker. Used in E. coli NM522 to add the C. glutamicum-specific DNA-methylation pattern to the 
integrative transformation vector
[34]
 pClik int sacB Integrative transformation vector for C. glutamicum with MCS, ORI for E. coli, and KanR and sacB as selection 
markers
[58]
 pClik int sacB tufp-
davBA
Integrative transformation vector for genome-based implementation of davBA genes from P. putida KT2440 into 
the bioD locus of C. glutamicum
This work
 pClik int sacB ∆lysE Integrative transformation vector for deletion of the lysine exporter lysE [12]
 pClik int sacB ∆gabT Integrative transformation vector for deletion of the 5-aminovalerate transaminase gene gabT This work
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salt medium with glucose as the carbon source [61]. The 
medium contained: (A) 500  mL salt solution (1  g NaCl, 
55 mg MgCl2·7H2O and 200 mg CaCl), (B) 100 mL sub-
strate solution (100  g  L−1 glucose), (C) 100  mL buffer 
solution (2 M potassium phosphate, pH 7.8), (D) 100 mL 
solution B (150 g L−1 (NH4)2SO4, pH 7.0), (E) 20 mL vita-
min solution (25 mg L−1 biotin, 50 mg L−1 thiamine·HCl 
and 50 mg L−1 pantothenic acid), (F) 10 mL FeSO4-solu-
tion (2 g L−1 FeSO4, pH 1.0), (G) 10 mL 100× trace ele-
ments [62] and (H) 1 mL DHB-solution (30 mg mL−1 of 
3,4-dihydroxybenzoic acid in 0.3  M NaOH) adjusted to 
1 L with milliQ. Solutions were separately sterilized by 
autoclaving (A–D) or by filtration (E–H). The different 
medium compounds were combined at room tempera-
ture freshly before use.
Fed‑batch cultivation in stirred tank bioreactors
The production performance of the optimized 5-amino-
valerate-producer C. glutamicum AVA-3 was evaluated 
in a fed-batch process. This was carried out in a complex 
molasses-based medium, containing per liter: 72.4 g beet 
molasses, 35 mL corn steep liquor, 40 g (NH4)2SO4, 99 g 
glucose·H2O, 250 µL H3PO4 (85 %), 11 mg FeSO4·7H2O, 
10 mg citrate, 9 mg biotin, 17.5 mg thiamine·HCl, 60 mg 
pantothenic acid Ca-salt, 18 mg nicotinamid, 6 mg ribo-
flavin, 6  mg FAD, 250  mg KH2PO4, 100  mg MgSO4. 
The initial batch was started in a volume of 300  mL in 
a 1000  mL bioreactor (SR0700ODLS, DASGIP AG, Jül-
ich, Germany) and inoculated with cells as previously 
described [13]. Dosing of the feed (650 g L−1 glucose·H2O, 
162.5 g L−1 beet molasses, 40 g L−1 (NH4)2SO4, 6 mg L−1 
riboflavin, 6 mg L−1 FAD) was initiated when the sugar 
concentration dropped below 20  g  L−1 and adjusted to 
maintain glucose concentration constant above 20 g L−1. 
The cultivation temperature was kept constant at 30  °C 
via the CWD4 bioblock (DASGIP AG, Jülich, Germany). 
The pH and the pO2 level were monitored online with a 
pH electrode (Mettler Toledo, Giessen, Germany) and a 
pO2 electrode (Hamilton, Höchst, Germany). The pH was 
kept constant at 6.9 ± 0.1 by automated addition of 25 % 
NH4OH (MP8 pump system, Eppendorf, Hamburg, Ger-
many). The dissolved oxygen level was maintained at sat-
uration above 30 % by variation of the stirrer speed and 
the aeration rate. Data acquisition and process operations 
were controlled by the DAGIP control software (DASGIP 
AG, Jülich, Germany).
Substrate and product quantification
Amino acids and 5-aminovalerate were quantified by 
HPLC, using α-aminobutyric acid as internal stand-
ard [63] with a modified gradient (0 min: 70 % eluent A; 
14 min: 56 % eluent A; 14.5 min: 0 % eluent A; 16.5 min: 
0 % eluent A; 17 min: 70 % eluent A; 19 min: 70 % elu-
ent A). Samples from fed-batch fermentation were addi-
tionally diluted with MilliQ water prior to dilution with 
the internal standard to account for the detector limit 
(<1.5  mM). Quantification of glucose and organic acids 
was carried out by isocratic HPLC (Agilent 1260 Infin-
ity Series, Waldbronn, Germany) comprising a degasser 
(G4225A), an autosampler (G1329B) including thermo-
stat (G1330B), an isocratic pump (G1310B), a column 
oven (G1316C), and a refraction index (RI) detector 
(G1362A). Separation was conducted on an Aminex 
HPX-87H column (300  ×  7.8  mm; Bio-Rad, München, 
Table 3 Description of primers that were used in the present work for genome-based integration of  tuf-promoter con-
trolled davBA genes from P. putida in the bioD locus (PRdavBA_1–PRdavBA_10) and for deletion of the gabT gene (PRgabT_1–
PRgabT_4) in C. glutamicum
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Germany) at 55 °C. As mobile phase 3.5 mM H2SO4 was 
used at a flow rate of 0.8 mL min−1. The injection volume 
was 20  µL. For sugar analysis of supernatant samples 
from fed-batch fermentation, a Metacarb 87C column 
(300 × 7.8 mm; Agilent, Darmstadt, Germany) with Met-
acarb 87C guard column (50 × 7.8 mm; Agilent, Darm-
stadt, Germany) and additional Micro-Guard De-Ashing 
Refill Cartridges (Bio-Rad, München, Germany) was used 
at 85  °C with demineralized water as mobile phase at a 
flow rate of 0.4  mL  min−1. If appropriate, samples were 
diluted prior to analysis. Refraction index was used for 
detection. Concentration of cell dry mass (CDM) was cal-
culated from the optical density using a correlation factor 
of CDM [g/L] = 0.32 × OD660. This was determined as 
described previously [61] for the here used UV-1600PC 
spectrophotometer (VWR, Hannover, Germany).
Determination of enzyme activity
Crude cell extracts were prepared from exponentially 
growing cells by mechanical cell disruption. Cultivation 
and harvest procedure was carried out as previously 
described [29]. Aliquots of 1  mL cell suspension were 
then transferred into FastPrep®-24 vials (MP Biomedi-
cals, Illkirch-Graffenstaden, France) containing silica 
beads (Ø 0.1  mm) and cell disruption was carried out 
in 2  ×  30  s cycles at 5000  rpm (Precellys®-24, PeqLab, 
Hannover, Germany) including 1  min cooling pauses 
on ice. Removal of cell debris and protein quantification 
was performed as previously described [61]. The proto-
col for subsequent quantification of the conversion rate 
of l-lysine into 5-aminovalerate, comprising the lumped 
activity of lysine monooxygenase and 5-aminovaleramide 
amidase, was based on previous protocols [19, 21]. The 
final reaction mixture of 5 mL contained 100 mM phos-
phate buffer (pH 7.5), 15 mM l-lysine, and 50 µL mL−1 
of crude cell extract (0.5  mg  mL−1 of protein). Incuba-
tion was carried out at 30 °C and 230 rpm on an orbital 
shaker (Multitron, Infors AG, Bottmingen, Switzerland) 
in 50  mL baffled shake flasks. Samples were regularly 
taken and thermally inactivated (5 min, 100  °C, Therm-
omixer F1.5, Eppendorf, Hamburg, Germany). l-lysine 
consumption and 5-aminovalerate formation were quan-
tified by HPLC as given above. Negative controls were 
conducted without the addition of crude cell extract and 
l-lysine, respectively. Moreover, the crude cell extract of 
the parent strain C. glutamicum LYS-12 was analyzed to 
account for potential non-DavBA associated enzymatic 
reactions.
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